Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine

US8445494B2 · kind B2 · utility

Assignees

• Bristol-Myers Squibb Company · US
• ALBANY MOLECULAR RESEARCH, INC. · US

Inventors

• Jun Qiu · Kendall Park, US
• Qi Gao · Shanghai, CN
• Shuang Liu · Schenectady, US
• Matthew Isherwood · Amherst, US

Key dates

• Filing date: Jun 4, 2009
• Grant date: May 21, 2013
• Expiry date: Jun 4, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F5/025
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.